IMDRF's AI/ML Lifecycle Draft and What Continuous Oversight Means for MedTech

📝 From the Editor

This week's regulatory signals point in one direction: continuous oversight, continuous evidence, continuous accountability. In Martin King's latest Regulatory Roundup, he frames it clearly — AI is forcing both manufacturers and regulators to rethink long-standing static models, with adaptive systems emerging where learning, monitoring, and improvement are ongoing.

That shift is showing up across the week — from the new IMDRF AI/ML lifecycle draft, to EUDAMED's fast-approaching May 28 mandatory date, to fresh MDCG classification guidance, to honest conversations about MDR/IVDR notified body queue times. The static-approval era is winding down. Lifecycle accountability is the new baseline.

Heading to RAPS Euro Convergence in Lisbon next week — if you're going, let's connect.

— Sean Smith

🧠 Featured Post

IMDRF AI/ML Lifecycle Draft — From Launch Approval to Continuous Lifecycle Accountability

Bioexcel summarized the implications of the new IMDRF AI/ML Lifecycle Draft, signaling a clear shift in how AI-enabled medical devices will be regulated globally.

AI-enabled devices will no longer be evaluated only at launch — they will be assessed based on how well they are governed, monitored, and controlled over time. The focus moves toward continuous lifecycle accountability, covering data quality and bias mitigation, real-world performance monitoring, and model drift.

For MedTech teams, this is a fundamental shift in how AI compliance will be defined. View the post >>

📬 In Case You Missed It

More than 150 people joined last Friday's MLVx Friday in Focus session with Leon Doorn for a practical discussion on AI and ML 510(k) submission lessons learned.

Drawing from direct experience, Doorn walked through where teams lose time, how validation burden can escalate quickly, and why early strategic decisions carry through the entire submission process. "My first FDA submission with an AI ML system was not that successful and it led to a very lengthy, complicated process and I learned a lot from it," he said.

🧠 One of the clearest takeaways from the session was his advice to keep the first submission focused: "Start small. Clear first. Expand later."

He also emphasized that cybersecurity and submission readiness need to be built into the work early. "Cybersecurity and SBOM are engineering work," he said.

The replay is now available >>

📌 This Week's Top Posts

(In no special order)

• Dr. med. Katharina discussed the importance of including procedure-related risks alongside device risks in clinical evaluations.
• Hidden risks in implant delivery systems on design, contamination, and patient outcomes, explored by David L. Stark.
• MedBoard underlined the recent MDCG 2021-24 Rev.1 update and its key classification changes under MDR.
• The role of hardware decisions in achieving EU HTA compliance and enabling high-quality clinical data, highlighted by Farida Ali.
• Scilife clarified QP and PRRC roles in batch release and regulatory compliance oversight.
• The implications of the new IMDRF AI/ML lifecycle draft and its shift toward continuous lifecycle oversight, revealed by Bioexcel.
• Clinical dilemmas around trusting AI versus clinician judgment in decision-making underscored by Sigrid Berge van Rooijen.
• EU MDR Compliance shared MDR/IVDR CE certification timelines and delays driven by notified body capacity.
• The upcoming EUDAMED mandatory use and key readiness steps for market access, detailed by Imen Ben Slama.
• David Pudwill cautioned Class I startups against overapplying ISO 13485 requirements.

🎯 Featured Event

Innovation Summit Dublin 2026

April 28–30, The Shelbourne Hotel, Dublin

Innovation Summit Dublin 2026 brings together start-ups, investors, strategics, and industry leaders to connect, collaborate, and explore what is next in medical technology.

Register Now >>

🗓️ Upcoming Events & Webinars

• April 28–30, 2026 | The Shelbourne Hotel, Dublin – Innovation Summit Dublin 2026.
• April 30, 2026 | 12:00 PM ET – Why MedTech Launches Stall: Aligning Regulatory, Reimbursement, and Commercial Strategy Earlier, featuring Michelle Lott (leanRAQA), Renae Franz (leanRAQA), and Fernanda Nusbaum (TTi Health).
• May 1, 2026 | 11:00 AM ET – EUDAMED Is Coming Fast: How to Turn Existing Documentation into Submission-Ready Files, featuring Sam Patton, Founder of EUDAPrep. Focused on taking existing documentation and preparing it for EUDAMED without rebuilding from scratch.
• May 5–8, 2026 | Lisbon Congress Centre – RAPS Euro Convergence 2026.
• May 8, 2026 | 11:00 AM ET – First-in-Human Clinical Trials in Latin America: What MedTech Teams Need to Know Before They Expand, featuring Julio G. Martinez-Clark, CEO of bioaccess®.
• May 15, 2026 | 11:00 AM ET – The QMS conversation your clients are having without you: From compliance advisor to embedded QMS partner in 90 days, featuring Charles Rollet, CEO of TraceX.

💥 Weekly 510(k) Roundup

April 20, 2026 | From Marcus Engineering, LLC

55 total clearances this week across multiple categories, including 8 first-time clearances (🚀).

Featured first-time clearances:

• 🚀 Conavi Medical – Novasight Hybrid System: Combines IVUS and OCT into one system, giving physicians a more complete, real-time view inside arteries during heart procedures without switching tools mid-procedure.
• 🚀 Advanced Sterilization Products – STERRAD 100NX with ALLClear Technology: Adds built-in checks that confirm instruments are truly ready for use, shifting from trusting the workflow to actively confirming it.
• 🚀 Pontemed AG – PELVIPOWER PelvicFMS: Uses functional magnetic stimulation to treat pelvic floor dysfunction through a hands-free, non-invasive chair-based system.

Full breakdown available in the April 20, 510(k) Roundup.

📋 Regulatory Roundup

April 20, 2026 | By Martin King

This week's global regulatory signals point in one direction: continuous oversight, continuous evidence, continuous accountability.

AI is forcing both manufacturers and regulators to rethink long-standing static models. Adaptive systems are emerging, where learning, monitoring, and improvement are ongoing. At its core, AI is helping accelerate continuous refinement — supporting faster alignment and better decision-making across the lifecycle.

Regulatory is becoming increasingly strategic, while Quality remains the procedural engine. Risk-based approaches are essential to ensure data quality, availability, and control.

Explore the update >>

🔥 Postscript

IMSC26 – International MedTech Safety Conference 2026

Join me, June 2–5, 2026 | Boston - IMSC26, featuring Dr. Michelle Tarver, FDA Director of CDRH, and a host of expert speakers. IMSC26 brings together MedTech professionals, regulators, and technical experts focused on safety, risk, and AI. Virtual or In-person.

Special MLV Discount Codes:

• $200 off General Registration (in-person OR virtual): MLV$200
• Startup: Start$250 – $250 off in-person registration
• Startup Education Day: StartEd$50 – $50 off

Register Now >>

Sean 🐝